Boehringer Ingelheim Obtains Ad-interim Injunctions On 4 Indian Pharma Cos

Multinational drug major Boehringer Ingelheim (BI) has obtained ad-interim injunctions against four domestic pharmaceutical -- Eris Lifesciences, Emcure Pharma, Optimus Pharma and MSN Laboratories. These had launched generic versions of Boehringer Ingelheim’s patent-protected drug Linagliptin, which is marketed under the brand name Trajenta.

The company also secured injunctions against Dr Reddy's Laboratories (DRL) and MSN Laboratories earlier for its diabetic drug Empagliflozin marketed as Jardiance in India.

Also, the company had secured an ad-interim injunction against Macleods Pharma for its Linagliptin drug, which was eventually made absolute.

"The recent injunctions restrain the domestic pharma from infringing the patent of Linagliptin by advertising, launching, making, using, offering for sale, selling, importing and/or exporting in any form in India either by themselves or through their directors, partners licenses, stockist and distributors, agents etc., jointly and severally until the next date of hearing," BI said in a statement here.

Boehringer Ingelheim holds a valid patent for Linagliptin in India until August 2023.

Vani Manja, Managing Director, Boehringer Ingelheim India, said “The swift and just actions from the High Court over the past nine months have reaffirmed our faith in the Indian legal system in securing the enforcement of patent rights and upholding of patient interests. This also underlines the strength of Boehringer Ingelheim’s patents.

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

RECENT NEWS

Central Banks And The Economic Horizon: Steering Through Uncertaintie

In the evolving landscape of global financial markets, the strategic role of central banks has come under intense scruti... Read more

Transforming Financial Operations With Robotic Process Automation

Author: Ricardo Goulart                           ... Read more

The Role Of Machine Learning In Fraud Detection

        Author: Gerardine Lucero                  &nbsp... Read more

Principles Of Islamic Banking And Finance

When it comes to banking, a significant new contender has entered the ring. The principles of Islamic banking and financ... Read more

The Role Of Central Banks In Global Economy

The role of central banks in global economy is a stimulating topic that requires profound understanding. Commonly, centr... Read more

History Of Banking Evolution In The 21st Century

Throughout time, the banking sector has assumed a central role in the smooth functioning of economies, generating growth... Read more